Consolidating both teams in the same larger, more modern office in Warsaw, Poland will accommodate continuing growth, improve internal and external communications and support “cost containment for shared services”.
PRA Phase I to IV trials in Poland are “achieving high patient recruitment and accessing excellent quality data”, Susan Stansfield, executive vice president (EVP), product registration, Europe, Africa and Asia-Pacific, told Outsourcing-Pharma.
“Solid increases in the placement of clinical studies” have been achieved, said Stansfield, with PRA experiencing “growth rates ahead of the market”. PRA “fully expects” growth in Poland to continue, citing European Medicines Agency (EMA) data as evidence of the market’s strength.
In Poland PRA provides feasibility, site start-up, site management and monitoring of Phase I to IV clinical trials. This is supported by medical affairs, project management and quality assurance services.
Special patient groups are accessed for specific Phase I needs. This is handled by the early development services team who establish Phase I study environments within central medical facilities that specialise in treating target patient populations.
Geographic expansion at PRA is underpinned by a patient-driven medical informatics technology. Using the system PRA can “estimate potential patient access that would result from moving into new territories and expanding in existing ones”, said Stansfield.
“We expect to see further growth in Eastern Europe, Middle East and Africa, Asia and Latin America”, said Stansfield, and PRA is “growing and consolidating in these regions, opening new facilities to house our staff as appropriate”.